ClinicalTrials.gg
RecruitingNCT06869252Updated May 31, 2025

Autologous Adipose Cells Therapy

A Phase 1/2 interventional study of Autologous Adipose Cells Therapy in Hair Loss/Baldness, Wrinkle Appearance and Volume, sponsored by CERM INC.. Recruiting at 2 sites in United States. Open to participants aged 21 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-05-31.

Sponsored by CERM INC. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
21 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 217 studies in Alopecia with a site in United States — 43 open to participants now, 63 under way, 6 of them phase 3. Alopecia · United States.

Planned enrollment
101st of 204
40 · median 40
Started
2025
with 19 others
Phase 1/2
7 of 217
2 open now
Primary completion
2025-11
later than 11 of 62 live
Registered
185th of 217
by date

Among the 217 studies in Alopecia with a site in United States, this one is the 101st largest by planned enrollment of the 204 interventional ones that give a count, is one of 20 that started in 2025, is one of 7 in phase 1/2, reaches primary completion later than 11 of the 62 other live ones, and was the 185th registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 127 are open to participants now.

Browse Alopecia studies →

Open to participants now

43 of the 217 studies in Alopecia with a site in United States are open now. Recruiting first, the newest first:

37 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Alopecia studies recruiting now, 24 (32%) set no upper age limit and 47 (63%) stop at 75 or younger; 10 take children under 18; 24 take healthy volunteers.

This study: 21 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 217 studies in Alopecia with a site in United States, or all of them as a file.
02

Study summary

Autologous Adipose Cell Therapy is a series of process designated to address the demerits of the traditional autologous fat grafting and dermal fillers, while enhancing the versatility and aesthetic outcomes. In this study, the goal is to evaluate the safety and efficacy of Autologous Adipose cell Therapy for skin rejuvenation and hair improvement in human application.

Read the detailed description

Autologous fat grafting (AFG) and injection of dermal fillers are the most prevailing aesthetic procedures in the cosmetic field for skin rejuvenation and hair restoration. High degree of biocompatibility and biodegradability of dermal fillers contribute significantly to their effectiveness in skin rejuvenation and hair restoration; however, the results are typically not enduring. On the other hand, autologous fat grafting is increasingly recognized for its applications not only in skin rejuvenation, but also breast augmentation and the treatment of arthritis. Fat fillers are fully biocompatible to the recipient, due to the use of autologous cell, the effects generally persist longer than those achieved with dermal fillers. Nonetheless, unprocessed lipoaspirate collected through liposuction procedure has a heterogeneous composition, which potentially leads to uneven distribution of adipose tissu resulting in formation of lumps or nodules at the recipient's site. Volume retention following autologous fat grafting is not solely affected by the resorption rate of adipose cells, but also impacted by re-uptake rate of other components of lipoaspirate. Autologous Adipose Cell Therapy seeks to enhance the current autologous fat grafting by isolating early-stage adipose cells from lipoaspirate and optimizing the number of adipocytes cells within the fat filler through cell property of differentiation. The purpose of this study is to assess the safety, feasibility, and efficacy of Autologous Adipose Cell Therapy for skin rejuvenation and hair improvement in human subjects. The eligibility of participants who are interested in participating in this study will be determined based on the inclusion and exclusion criteria listed in the study protocol. The in-charge plastic surgeon will monitor and evaluate the treatment outcomes in participants over a six-months period after the administration of Autologous Adipose Cell Therapy.

03

Conditions studied

  • Hair Loss/Baldness
  • Wrinkle Appearance
  • Volume
  • Fine Lines
  • Skin Elasticity
  • Hair Thinning
  • Skin Pigmentation
  • Skin Texture

Keywords

  • Adipose Cells
  • Adipocytes
04

Who can participate

Ages eligible
21 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Outpatients who express interest in skin rejuvenation, and/or who are experiencing skin conditions, such as winkles, fine lines, loss of skin elasticity, skin pigmentation, scarring.
  2. Outpatients who are experiencing hair loss or hair thinning
  3. Provision of signed and dated form
  4. Clearly stated willingness to comply with all the procedures of the study and availability of the study
  5. Female and Male aged between 21 to 80 years old 6 Medical clearance by family doctor

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy or lactation
  2. Known allergic reaction to components of cell culture media
  3. Chronic disease , e.g. cardiovascular disease, diabetes, chronic kidney disease, seizures
  4. Chronic infections, e.g. skin fungi infection, psoriasis
  5. Chronic wound healing
  6. Currently taking hormone therapy
  7. History of cancers and active cancers
  8. Viral infection, e.g. , , influenza, coronaviruses.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Autologous Adipose Cells Therapy

    Biological: Autologous Adipose Cells Therapy

Interventions

  • BiologicalAutologous Adipose Cells Therapy

    Participants will receive Autologous Adipose Cells therapy treatment, and the safety and efficacy of the treatment will be monitored by the primary investigator up to 25 weeks.

06

What researchers measure

Primary outcomes

  1. Outcome Comparison Survey

    30 people will be randomly selected to rank the level of improvement by comparing the images captured at pro and post-treatment from Imaging assessment. Scale of Improvement: * No Improvement(0%) * Minimal Improvement(1% - 25%) * Moderate Improvement(26% - 50%) * Significant Improvement(51% - 75%) * Major Improvement(76% - 100%)

    Time frame: The end of the study (Week 20 to 25)

  2. Participant Satisfaction Survey

    Participants will be requested to complete a list of questions related to their experience and satisfaction of autologous adipose cell therapy in each study visit for result evaluation. 1-to-5 Scales: * 1 being "very poor" and 5 being "excellent" * 1 being "very dissatisfied" and 5 being "very satisfied"

    Time frame: From first post-treatment follow-up visit to the last follow-up visit at week 16 to week 25

  3. Imaging Assessment

    Digital images of the target site will be captured for each participant both prior to and following autologous adipose cell therapy for the purpose of outcome evaluation. The comparison of pre- and post-treatment images will be utilized in the "Outcome Comparison Survey" and the "Visit Evaluation Report" to assess the degree of improvement, based on the established assessment parameters for Autologous Adipose Cell Therapy treatment.

    Time frame: From first pre-treatment visit to the last follow-up visit at week 16 to week 25

  4. Case Report Form

    A comprehensive medical document will be prepared by the responsible plastic surgeon which outlines the key details of each stage of the treatment process and aspects based on each participant's case. This document will include a thorough description of the patient's presenting medical conditions, the surgical procedures performed, post-treatment progress, any adverse events that occurred, and the final outcomes.

    Time frame: The report will be completed at the end of the study (Week 20 to 25), but highlights would be recorded in this document during every visit.

  5. Visit Evaluation Report

    During each post-treatment visit, the responsible plastic surgeon will assess the treatment outcomes and evaluate the degree of improvement by comparing the pre-treatment image with the current post-treatment image. Scale of Improvement: * No Improvement(0%) * Minimal Improvement(1% - 25%) * Moderate Improvement(26% - 50%) * Significant Improvement(51% - 75%) * Major Improvement(76% - 100%) Assessment Parameters: Skin: * Radiance * Texture * Firmness * Wrinkles \& Fine Lines * Spot Hyperpigmentation * Tone * Redness \& Inflammation * Pore Size Hair: * Density * Thickness * Visual Appearance * Texture (Smoothness \& Frizz Control) * Shine * Scalp Health

    Time frame: From first post-treatment follow-up visit to the last follow-up visit at week 16 to week 25

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Bellini E, Grieco MP, Raposio E. The science behind autologous fat grafting. Ann Med Surg (Lond). 2017 Nov 10;24:65-73. doi: 10.1016/j.amsu.2017.11.001. eCollection 2017 Dec. PubMed 29188051 ↗
  • Sutcliffe H, Rawlinson PS, Thakker B, Neary R, Mallick N. Factitious proteinuria: diagnosis and protein identification by use of isoelectric focusing. Clin Chem. 1988 Aug;34(8):1653-5. PubMed 3402073 ↗
  • An Y, Wang G, Li X, Zhen Y, Zhao J, Li D. Rhinoplasty with Simultaneous Autologous Full-Face Fat Transfer for Asian Facial Contouring Balance: A Retrospective Study. Aesthetic Plast Surg. 2023 Apr;47(2):746-756. doi: 10.1007/s00266-022-03064-6. Epub 2022 Aug 30. PubMed 36042025 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2025; primary completion for Nov 2025, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2025
First posted
Mar 11, 2025
StartEst.
Aug 1, 2025
Primary completionEst.
Nov 1, 2025
CompletionEst.
Feb 1, 2026
Last update
May 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06869252
Lead sponsor
CERM INC.
Responsible party
Sponsor
First posted
Mar 11, 2025
Start date
Aug 1, 2025 (estimated)
Primary completion
Nov 1, 2025 (estimated)
Completion
Feb 1, 2026 (estimated)
Last update
May 31, 2025

Study contacts

Ankeet Dixit
Contact
ankeetdixit@cermbio.com
813-992-2521
Wing Nam Fung
Contact
wingnam@cermbio.com
207-671-9370
Dr. Abdollah M. Malekzadeh, MD, MD
principal investigator · The Centre for Cosmetic Surgery & Medicine
Dr. Arun Kumar, PhD
study director · CERM INC.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion